CONTINGENT LIABILITIES (Narrative) (Details) € in Thousands, $ in Thousands |
1 Months Ended | 12 Months Ended | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Apr. 05, 2023
EUR (€)
|
Dec. 14, 2021
EUR (€)
|
Apr. 24, 2024
EUR (€)
|
Nov. 17, 2023
CAD ($)
|
Oct. 31, 2023
CAD ($)
|
Dec. 22, 2022
CAD ($)
|
Dec. 22, 2022
EUR (€)
|
Nov. 19, 2021
EUR (€)
|
Mar. 23, 2021 |
Dec. 31, 2025
CAD ($)
|
Dec. 31, 2024
CAD ($)
|
Dec. 31, 2023
CAD ($)
|
|||
| Disclosure of contingent liabilities [line items] | ||||||||||||||
| Amount of class action group incurred damages | € | € 948 | € 7 | € 54 | |||||||||||
| Test kits purchased | $ 1,540 | € 1,046 | ||||||||||||
| Percentage of German basis rate | 5.00% | 5.00% | 5.00% | |||||||||||
| Test kits purchased | 300,000 | 300,000 | 300,000 | 4.3 | ||||||||||
| Lawsuit for payment | € | € 1,046 | |||||||||||||
| Plaintiffs claiming damages amount | $ | $ 15,000 | |||||||||||||
| Aggravated, exemplary and punitive damages | $ | $ 1,000 | |||||||||||||
| Failure to file penalty in aggregate amount | $ | $ 319 | |||||||||||||
| Outstanding loan with aggregate principal and accrued interest balance | $ | $ 15,269 | $ 15,611 | ||||||||||||
| Legal services fees | $ | [1] | $ 912 | $ 724 | $ 852 | ||||||||||
| Adjupharm Gmbh [Member] | ||||||||||||||
| Disclosure of contingent liabilities [line items] | ||||||||||||||
| Total amount Clongene COVID-19 tests | € | € 941,897 | |||||||||||||
| Test kits purchased | 4.3 million Clongene COVID-19 tests, of which Uniclaro claims to have a payment claim against the Company for a partial delivery of 380,400 Clongene COVID-19 tests | |||||||||||||
| Outstanding receivable | € | € 948 | |||||||||||||
| Uniclaro GmbH (“Uniclaro”) [Member] | ||||||||||||||
| Disclosure of contingent liabilities [line items] | ||||||||||||||
| Total amount of placed an order Uniclaro GmbH | € | € 4,300 | |||||||||||||
| ||||||||||||||
| X | ||||||||||
- Definition The amount of outstanding funds that the entity is obligated to repay. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table. No definition available.
|
| X | ||||||||||
- Definition The amount of outstanding commitments made by the entity in related party transactions. [Refer: Total for all related parties [member]] Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition It represents aggravated, exemplary and punitive damages. No definition available.
|
| X | ||||||||||
- Definition Represents the amount of class action group incurred damages. No definition available.
|
| X | ||||||||||
- Definition It represents failure to file penalty in aggregate amount. No definition available.
|
| X | ||||||||||
- Definition It represents lawsuit for payment. No definition available.
|
| X | ||||||||||
- Definition Percentage of german basis rate. No definition available.
|
| X | ||||||||||
- Definition It represens plaintiffs are claiming damages amount. No definition available.
|
| X | ||||||||||
- Definition Test kits purchased. No definition available.
|
| X | ||||||||||
- Definition test kits purchased. No definition available.
|
| X | ||||||||||
- Definition Total amount Clongene COVID-19 tests. No definition available.
|
| X | ||||||||||
- Definition Total amount of placed an order Uniclaro GmbH. No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|